GlassScriptPhysician profile
Roberta Champouillon
NPI 1134850779
$6,002.57
in general payments reported to CMS, 2019-2025
26 companies · $1,340 in 2025
The $1,340 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,302 · 2023: $1,768 · 2024: $1,592 · 2025: $1,340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,602 · Education: $98.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,602.04 |
| Education | $98.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $955.48 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $876.24 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $859.32 | 2023-2025 | Caplyta |
| Novo Nordisk INC | $472.14 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Alkermes, INC. | $423.36 | 2022-2025 | Lybalvi, Aristada, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $375.58 | 2022-2023 | Austedo, Austedo Xr |
| Lilly USA, LLC | $375.26 | 2022-2025 | Mounjaro, Zepbound |
| Idorsia Pharmaceuticals US INC | $332.07 | 2022-2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $232.68 | 2022-2025 | Rexulti |
| Exact Sciences Corporation | $223.24 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $161.06 | 2022-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $127.29 | 2024-2025 | Veozah |
| Genzyme Corporation | $124.99 | 2022 | |
| Argenx US, INC. | $99.64 | 2023 | Vyvgart |
| Acella Pharmaceuticals, LLC | $76.51 | 2024-2025 | NP Thyroid 60 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $68.53 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $37.31 | 2025 | |
| Lundbeck LLC | $29.43 | 2025 | Rexulti |
| Inspire Medical Systems, INC. | $27.32 | 2025 | Inspire |
| Allergan, INC. | $25.82 | 2022 | |
| Angiodynamics, INC. | $24.74 | 2024 | Auryon Laser System 100-120 Vac |
| Merck Sharp & Dohme LLC | $16.29 | 2022 | |
| Avion Pharmaceuticals | $15.89 | 2024 | NP Thyroid 60 |
| Alnylam Pharmaceuticals INC. | $15.27 | 2022 | |
| Abbott Laboratories | $13.78 | 2024 | Eterna |
| Glaxosmithkline, LLC. | $13.33 | 2023 | Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberta Champouillon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.